A Study of BMS-663513 in Combination With Chemoradiation in Subjects With Non Small Cell Lung Carcinoma (NSCLC)
- Registration Number
- NCT00461110
- Lead Sponsor
- Bristol-Myers Squibb
- Brief Summary
- The purpose of this study is to determine the maximum tolerated dose and assess the safety and tolerability of escalating doses of BMS-663513 when given in combination with either radiotherapy alone or radiotherapy plus paclitaxel and carboplatin. 
- Detailed Description
- Not available 
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 35
Inclusion Criteria
- NSCLC who are eligible to receive a 6 week course of RT
- Part 1 - not candidates for definitive RT
- Part 2 - candidates for definitive RT
Exclusion Criteria
- Severe COPD, pulmonary infection or interstitial pneumonitis
- Recent cellulitis
- Autoimmune disease
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
- Group - Intervention - Description - 1 - BMS-663513 - Active - 2 - BMS-663513 - Active 
- Primary Outcome Measures
- Name - Time - Method - To determine the MTD and assess safety and tolerability of single ascending doses of BMS-663513 when given in combination with radiotherapy alone or radiotherapy plus paclitaxel and carboplatin to subjects with Non Small Cell Lung Carcinoma - throughout the study 
- Secondary Outcome Measures
- Name - Time - Method - Assess the PKs of BMS-663513 and the effect of BMS-663513 on immune system markers - end of study - Describe anti-tumor activity - throughout the study - Obtain archival tissue for predictive marker research - at screening - Obtain blood and plasma for exploratory research - several timepoints throughout the study 
Trial Locations
- Locations (4)
- The Cancer Institute Of New Jersey 🇺🇸- New Brunswick, New Jersey, United States - Nyu Clinical Cancer Center 🇺🇸- New York, New York, United States - Thomas Jefferson Univ Hospital 🇺🇸- Philadelphia, Pennsylvania, United States - University Of Texas Southwestern Medical Center 🇺🇸- Dallas, Texas, United States The Cancer Institute Of New Jersey🇺🇸New Brunswick, New Jersey, United States
